Skip to main content

Development of RGD-therapeutics for cardio-metabolic disease

Project description

Addressing cardiovascular disease risks in diabetes patients

Diabetes is associated with microvascular diseases, primarily affecting the coronary arteries and the peripheral arteries. However, current diabetes therapies do not reduce cardiovascular events. In this context, the ERC-funded RGD-Diabetes project will search for a solution. Specifically, the research will focus on a circulating protein, IGF binding protein-1, which possesses several favourable characteristics (insulin sensitisation, amelioration of glucose intolerance, blood pressure lowering, reduced atherosclerosis and increased vascular repair). These effects are mediated by the interaction of the protein’s RGD-domain with cell-surface α5β1 integrin receptors, which increases insulin-stimulated glucose uptake in skeletal muscle cells and glucose-stimulated insulin secretion in pancreatic islets. The project will test whether RGD-integrin interaction could be exploited therapeutically in diabetes.

Host institution

UNIVERSITY OF LEEDS
Net EU contribution
€ 150 000,00
Address
Woodhouse Lane
LS2 9JT Leeds
United Kingdom

See on map

Region
Yorkshire and the Humber West Yorkshire Leeds
Activity type
Higher or Secondary Education Establishments
Other funding
€ 150 000,00

Beneficiaries (1)

UNIVERSITY OF LEEDS
United Kingdom
Net EU contribution
€ 150 000,00
Address
Woodhouse Lane
LS2 9JT Leeds

See on map

Region
Yorkshire and the Humber West Yorkshire Leeds
Activity type
Higher or Secondary Education Establishments
Other funding
€ 150 000,00